Single vs Double Lung Transplant for COPD: Which Is Better?

Research-informed explainer — last updated April 12, 2026

For patients with end-stage COPD, both single lung transplant (SLT) and bilateral lung transplant (BLT) can dramatically improve quality of life and extend survival — but bilateral transplant generally produces better long-term outcomes at the cost of greater surgical complexity. The right choice depends on your age, your lung function, how much your emphysema affects both lungs symmetrically, and what your transplant center recommends for your specific situation.

This explainer draws on pulmonary expertise from three physicians in the Convene directory. James Stoller at Cleveland Clinic, who serves as Chairman of the Education Institute, published ATS/ERS standards for alpha-1 antitrypsin deficiency — the genetic form of emphysema where transplant decisions are particularly complex — and co-authored a comprehensive care management study for COPD hospitalization prevention. Thomas Gildea, Head of Bronchology at Cleveland Clinic, published research on post-transplant airway complications including bronchial dehiscence and anastomotic stenosis, which are central to understanding how single versus bilateral transplant affects post-operative course. Manu Jain at Northwestern, whose work focuses on lung disease in cystic fibrosis patients, contributes comparative perspective on bilateral transplant outcomes in obstructive lung disease more broadly.

What's the difference?

In a single lung transplant, surgeons replace one diseased lung — typically the more severely affected one — through a thoracotomy incision on one side. The native lung remains in place on the other side. Surgery typically takes four to six hours, and recovery, while still major, is shorter than bilateral transplant.

A bilateral lung transplant replaces both lungs sequentially in the same operation. It is typically done through a clamshell incision (bilateral thoracotomy across the sternum) or bilateral sequential thoracotomies. Surgery takes longer, blood loss is greater, and the procedure may require cardiopulmonary bypass or extracorporeal membrane oxygenation (ECMO) support. Both lungs are exchanged, and nothing of the original lung function remains.

The reason bilateral transplant has become more common over time is cumulative survival evidence. Registry data from the International Society for Heart and Lung Transplantation (ISHLT) consistently show that bilateral lung recipients with COPD have better 5-year and 10-year survival than single lung recipients. One-year survival rates are broadly comparable between approaches (roughly 80–85%), but by five years the bilateral advantage becomes more pronounced, with some registry analyses showing 63% five-year survival for bilateral versus 48% for single lung.

At a glance

Why bilateral transplant produces better survival in COPD

The native emphysematous lung left in place after single lung transplant is a source of ongoing problems. Emphysematous tissue is hyperinflated and has low elastic recoil. After transplant, when one healthy lung is breathing efficiently, the remaining native lung can overexpand and compress the transplanted lung — a phenomenon called native lung hyperinflation. This can reduce the function of the transplanted lung, worsen gas exchange, and in severe cases cause mediastinal shift.

Bilateral transplant eliminates this problem. With both lungs replaced, there is no competing native tissue. Patients typically achieve higher post-transplant FEV1 values after bilateral transplant than after single lung transplant, reflecting more total functional lung volume. Higher FEV1 at one year post-transplant is one of the strongest predictors of long-term survival.

There is also an infectious risk from the native lung. In COPD caused by alpha-1 antitrypsin (AAT) deficiency — a genetic condition extensively studied by James Stoller and colleagues at Cleveland Clinic — emphysematous lungs may harbor chronic bacterial colonization [1, 3]. Leaving an infected or colonized native lung in place after single lung transplant can create an infectious reservoir that affects the transplanted organ. This concern is particularly relevant in cystic fibrosis (where bilateral transplant is mandatory because of bilateral infection) and may factor into some COPD cases as well.

Anastomotic complications after lung transplant

One of the technical risks unique to lung transplantation — distinguishing it from other solid organ transplants — is the vulnerability of the airway anastomosis. The bronchial anastomosis does not receive the same direct blood supply as the rest of the airway. Research from Thomas Gildea and colleagues at Cleveland Clinic, published in The Annals of Thoracic Surgery, examined outcomes in patients who developed anastomotic airway complications after lung transplant [6]. Among 272 transplant recipients studied, approximately 18% developed some form of anastomotic complication, ranging from bronchial necrosis to obstructive stenosis.

The survival impact was significant. Patients with treated anastomotic complications had equivalent early survival to those without complications (82% versus 80% at 12 months), but their late survival was substantially worse (60% versus 27% at 48 months) [6]. Bilateral transplant carries two bronchial anastomoses rather than one, which means twice the opportunity for this complication. However, modern bilateral transplant techniques and post-transplant bronchoscopic surveillance have reduced anastomotic complication rates considerably from historical figures.

Gildea's group at Cleveland Clinic also published on the management of bronchial dehiscence using self-expanding metallic stents, a bronchoscopic intervention that can salvage compromised anastomoses [5]. This work reflects how bronchoscopy expertise — not just surgical skill — has become central to post-lung transplant care, and why centers with high-volume bronchoscopy programs tend to have better post-transplant outcomes regardless of whether patients received single or bilateral transplants.

Age and how it affects the choice

Younger patients with COPD — generally under 60 — are more commonly offered bilateral transplant, and the survival data support this. Younger patients tolerate the more complex bilateral surgery better, and the long-term survival advantage is amplified over a longer projected lifespan. The additional years of benefit from bilateral transplant matter more when the patient has 20 or more expected post-transplant years ahead.

Older patients — particularly those over 65 — present a different calculus. The surgical stress of bilateral transplant is greater, recovery is more difficult, and the incremental long-term benefit may not outweigh the upfront perioperative risk. For older patients, single lung transplant offers a faster surgery, lower immediate risk, and still meaningful improvement in quality of life. This is why single lung transplant persists as a viable option even as bilateral transplant has become more common overall.

The trajectory of U.S. transplant practice reflects this shift. Data from the ISHLT registry show a gradual move toward bilateral transplant for COPD over the past two decades, driven by accumulating evidence of superior long-term survival. Single lung transplant now accounts for a smaller fraction of COPD transplants than it did in the early 2000s.

Alpha-1 antitrypsin deficiency: a distinct scenario

Patients with COPD caused by alpha-1 antitrypsin (AAT) deficiency — the most common genetic cause of early-onset emphysema — face specific considerations. The ATS/ERS standards for AAT deficiency co-authored by James Stoller address the natural history and treatment framework for this condition, including when transplant should be considered [1]. AAT deficiency causes pan-acinar emphysema that affects both lung bases early, making bilateral disease nearly universal by the time transplant is relevant.

For AAT-deficient patients, bilateral transplant is generally preferred because the underlying genetic defect has already damaged both lungs symmetrically, and the native lung complications of hyperinflation and colonization may be more pronounced. After bilateral transplant, the new donor lungs produce normal AAT (since the gene defect is hepatic in origin), so the transplanted lungs do not face the same protease-driven damage that destroyed the native tissue.

Cystic fibrosis and obstructive lung disease context

Manu Jain at Northwestern has published extensively on cystic fibrosis lung disease, CFTR modulator therapy, and infection control in CF patients [7, 8, 9]. In cystic fibrosis, bilateral lung transplant is not a choice — it is the standard of care, because leaving a chronically infected native CF lung in place would seed the transplanted lung with organisms that cannot be cleared. The bilateral CF experience has contributed substantially to the knowledge base for bilateral transplant technique, perioperative management, and post-transplant bronchoscopy.

CFTR modulator therapies like elexacaftor-tezacaftor-ivacaftor have now dramatically reduced the number of CF patients who progress to transplant — but the CF transplant literature continues to provide valuable data on bilateral lung transplant outcomes in young obstructive lung disease patients. The infection control and airway surveillance protocols developed in CF transplant centers often inform COPD transplant practices.

What matters most in your decision

The single most important factor in the single vs. bilateral transplant decision is your age and overall surgical fitness. For patients under 55 with good cardiac function and no major comorbidities, bilateral transplant is typically favored. For patients over 65 or those with significant comorbidities, single lung transplant is often the safer choice that still provides substantial benefit.

Your transplant center's volume and experience matters greatly. High-volume centers with experienced surgical and bronchology teams have substantially better outcomes than low-volume centers, regardless of whether single or bilateral transplant is performed. Centers that perform bilateral lung transplants routinely maintain the skills and post-transplant protocols that optimize outcomes for this more complex procedure.

Questions to ask your transplant team

• Based on my age, lung function, and general health, which approach do you recommend and why?
• Does the distribution of emphysema in my CT scan — bilateral versus predominantly one-sided — affect the recommendation?
• What are this center's annual volumes of single and bilateral lung transplants, and what are the one-year and five-year survival rates?
• If I have alpha-1 antitrypsin deficiency, does that change the recommendation toward bilateral transplant?
• What is the risk of native lung hyperinflation if I receive a single lung transplant, based on my specific anatomy?
• What does post-transplant bronchoscopic surveillance look like, and how does your center manage anastomotic complications if they arise?

The bottom line

Bilateral lung transplant produces better long-term survival than single lung transplant for most COPD patients, driven by the elimination of native lung hyperinflation and higher post-transplant lung function. Single lung transplant remains appropriate for older patients or those with significant comorbidities where the surgical risk of bilateral transplant outweighs the long-term benefit. The decision should be made at a high-volume transplant center with expertise in both approaches and strong post-transplant bronchoscopic surveillance capabilities.